Gustabor Phase 1 – KI-basierte Erstellung eines Ernährungsplans zum Ausgleich von Chemotherapie-bedingten Geschmacksstörungen

A non-interventional study of melphalan flufenamide (melflufen, Pepaxti) in combination with dexamethasone in patients with relapsed and/ or refractory multiple myeloma (RRMM) according to the approved label

A non-interventional study of melphalan flufenamide (melflufen, Pepaxti) in combination with dexamethasone in patients with relapsed and/ or refractory multiple myeloma (RRMM) according to the approved label

Nicht-interventionelle Beobachtungsstudie zur Bewertung der Lebensqualität (HRQoL) bei Patienten mit rezidiviertem und/oder refraktärem Multiplen Myelom, die eine vorherige Therapielinie erhalten haben und mit Isatuximab behandelt werden.

A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Real-World Outcomes of Adult Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Evidence from a Multicenter Retrospective Study.

Ohrakupressur bei Patienten mit Multiplem Myelom - eine randomisierte kontrollierte Studie

International, multicenter, non-interventional PASS study  to evaluatemthe effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myelom treated in real world settings

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy